vaccine children

Covaxin approved for Phase 2/3 clinical trials for children in 2-18 age group

Drugs Controller General of India (DCGI), the National Regulatory of India has approved indigenously developed Covid-19 vaccine, Covaxin for conducting Phase 2 and 3 clinical trials among children from 2 to 18 years of age.

Earlier in September 2020, Bharat Biotech, the developer of Covaxin conducted the trials for 12-65 years and the vaccine has already been approved for emergency use in persons affected with Covid-19 of age 18 years and above.

Under this phase of the trial now approved, 525 healthy volunteers will be tested. The vaccine will be given in two doses on days 0 and 28, says the Press Release issued by the Ministry of Health and Family Welfare.

Leave a Reply

Your email address will not be published. Required fields are marked *